|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakamura M, Iwahashi M, Nakamori M, Ojima
T, Katsuda M, Iida T, Hayata K, Kato T and Yamaue H: New prognostic
score for the survival of patients with esophageal squamous cell
carcinoma. Surg Today. 44:875–883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okumura H, Uchikado Y, Setoyama T,
Matsumoto M, Owaki T, Ishigami S and Natsugoe S: Biomarkers for
predicting the response of esophageal squamous cell carcinoma to
neoadjuvant chemoradiation therapy. Surg Today. 44:421–428. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Borghesi S, Hawkins MA and Tait D:
Oesophagectomy after definitive chemoradiation in patients with
locally advanced oesophageal cancer. Clin Oncol (R Coll radiol).
20:221–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Makino T, Yamasaki M, Miyata H, Tanaka K,
Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M and Doki
Y: Solitary lymph node recurrence of esophageal squamous cell
carcinoma: Surgical failure or systemic disease? Ann Surg Oncol.
23:2087–2093. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alexander BM, Wang XZ, Niemierko A, Weaver
DT, Mak RH, Roof KS, Fidias P, Wain J and Choi NC: DNA repair
biomarkers predict response to neoadjuvant chemoradiotherapy in
esophageal cancer. Int J tadiat Oncol Biol Phys. 83:164–171. 2012.
View Article : Google Scholar
|
|
7
|
Park SH, Jang KY, Kim MJ, Yoon S, Jo Y,
Kwon SM, Kim KM, Kwon KS, Kim CY and Woo HG: Tumor suppressive
effect of PARP1 and FOXO3A in gastric cancers and its clinical
implications. Oncotarget. 6:44819–44831. 2015.PubMed/NCBI
|
|
8
|
Hoeijmakers JH: Genome maintenance
mechanisms for preventing cancer. Nature. 411:366–374. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Juarez-Salinas H, Sims JL and Jacobson MK:
Poly(ADP-ribose) levels in carcinogen-treated cells. Nature.
282:740–741. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Durkacz BW, Omidiji O, Gray DA and Shall
S: (ADP-ribose)n participates in DNA excision repair. Nature.
283:593–596. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rouleau M, Patel A, Hendzel MJ, Kaufmann
SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev
Cancer. 10:293–301. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoeijmakers JH: DNA damage, aging and
cancer. N Engl J Med. 361:1475–1485. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Helleday T, Petermann E, Lundin C, Hodgson
B and Sharma RA: DNA repair pathways as targets for cancer therapy.
Nat Rev Cancer. 8:193–204. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rottenberg S, Jaspers JE, Kersbergen A,
van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M,
Zevenhoven J, Lau A, et al: High sensitivity of BRCA1-deficient
mammary tumors to the PARP inhibitor AZD2281 alone and in
combination with platinum drugs. Proc Natl Acad Sci USA. 105:pp.
17079–1784. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jelinic P and Levine DA: New insights into
PARP inhibitors' effect on cell cycle and homology-directed DNA
damage repair. Mol Cancer Ther. 13:1645–1654. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakogawa K, Aoki Y, Misumi K, Hamai Y, Emi
M, Hihara J, Shi L, Kono K, Horikoshi Y, Sun J, et al: Involvement
of homologous recombination in the synergism between cisplatin and
poly (ADP-ribose) polymerase inhibition. Cancer Sci. 104:1593–1599.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH and Compton CC: TNM seventh
edition: what's new, what's changed: Communication from the
international union against cancer and the American Joint committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gradwohl G, Ménissier de Murcia JM,
Molinete M, Simonin F, Koken M, Hoeijmakers JH and de Murcia G: The
second zinc-finger domain of poly(ADP-ribose) polymerase determines
specificity for single-stranded breaks in DNA. Proc Natl Acad Sci
USA. 87:pp. 2990–2994. 1990; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Atherton-Fessler S, Liu F, Gabrielli B,
Lee MS, Peng CY and Piwnica-Worms H: Cell cycle regulation of the
p34cdc2 inhibitory kinases. Mol Biol Cell. 5:989–1001. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hunter T: Protein kinases and
phosphatases: The yin and yang of protein phosphorylationand
signaling. Cell. 80:225–236. 1995. View Article : Google Scholar : PubMed/NCBI
|
